Business Context and Reporting Period
This Form 6-K filing by Haoxi Health Technology Ltd covers the month of February 2026, with the report dated February 10, 2026. The filing addresses the termination of a material definitive agreement regarding an at-the-market equity program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the status of a specific equity sales agreement.
Material Changes
- Termination of Sales Agreement: On February 7, 2026, the Company and Aegis Capital Corp mutually terminated the Sales Agreement entered into on January 23, 2026.
- Program Details: The terminated agreement allowed for the sale of up to $80 million of Class A ordinary shares.
- Execution Status: The Company did not sell any Class A Ordinary Shares pursuant to the Sales Agreement prior to its termination.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. The primary disclosure is the cessation of the equity distribution program, which eliminates the immediate risk of dilution from this specific mechanism but also removes a potential source of capital.
Investor Verification Checklist
- Verify the reason for the mutual termination of the $80 million at-the-market program with Aegis Capital Corp.
- Confirm whether the Company intends to establish a new equity distribution program in the near future.
- Review the Company's current cash position and liquidity needs given the termination of this potential funding source.
- Check for any subsequent filings regarding the status of the Form F-3 registration statement (File No. 333-287686).